University of California San Francisco
Give to UCSF
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s
UCSF scientists have found a set of autoantibodies that emerge in some MS patients years before symptoms.
New CAR-T gene therapy techniques could extend survival for patients with glioblastoma.
A study reveals the life-altering impact of COVID-19 on individuals who developed severe illness, the majority of whom had to be placed on mechanical ventilators. Two-thirds still had physical, psychiatric, and cognitive problems for up to a year later.
Intentional flu vaccine messaging, such as a brief video, flyer, or a scripted provider question, is enough to persuade many who visit emergency departments to receive the vaccination.
The COVID-19 virus can persist in the blood and tissue of patients for more than a year after the acute phase of the illness has ended.
A first of its kind study finds that the COVID vaccine is safe to administer during pregnancy, causing no abnormal delays when the infants were tested at 12 months and again at 18 months.
UCSF will launch the world’s first tissue bank with samples donated by patients with long COVID.
Cancer immunotherapy is hindered by the fact that engineered immune cells often get worn out and depleted before they've killed a tumor. A UCSF team has identified mutations that give cancerous lymphoma T-cells their superpower and transfer those genes into engineered, therapeutic immune cells.
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T
A team of researchers from UC San Francisco has found that Paxlovid did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.